Sumitomo Pharma Co., Ltd. DNPUF
11.91 USD 0.00 (+0.00%)
Regular-session close
10.50 Day range 10.50
8.41 52-week range 19.20
- YTD
- -17.06%
- 1 year
- -8.38%
News
businesswire.com Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced two oral presentations and two poster presentations at the 68th American Society of Hematology (ASH) Annual…
businesswire.com Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced that it has enrolled the required number of participants in its pivotal Phase 2 monotherapy trial for…
seekingalpha.com Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
cnbc.com Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment Shares of Japan's Sumitomo Pharma fell over 12%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease.
